Biocytogen Pharmaceuticals Co. Ltd.’s subsidiary Eucure Biopharma Co. Ltd. has granted Isu Abxis Co. Ltd. rights to use its humanized agonistic anti-CD40 antibody YH-003 to develop cancer drugs.
Radiopharmaceutical company Telix Pharmaceuticals Ltd’s TLX250-CDx (Zirconium (89Zr) TX250) met both primary and secondary endpoints in the phase III Zircon study in clear cell renal cell carcinoma, according to top-line data.
There are doubts about the future of GSK plc’s multiple myeloma drug Blenrep (belantamab mafodotin) after it failed to meet its goal of improving progression-free survival compared with standard chemotherapy in a confirmatory trial, placing its conditional approvals in the U.S. and Europe at risk.
Given Bioatla Inc.’s positive update from the study testing mecbotamab vedotin (BA-3011) in metastatic non-small-cell lung cancer sharpened investor thirst for more data by the end of this year, and Wall Street wanted to know how good the findings need to be in order to advance further.
At the end of September, C4 Therapeutics Inc. disclosed the U.S. FDA’s green light for the phase I/II trial with CFT-1946 in solid tumors, but the firm has piqued Wall Street’s interest more with another program due to face off with Bristol Myers Squibb Co. (BMS) in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).
Shares in Affimed AG gained as much as 28% during trading on Nov. 3 as the company unveiled continued good news from a phase I/II combination trial in CD30-positive lymphoma of its CD30-directed innate cell engager, AFM-13, and allogeneic natural killer (NK) cell therapy, as well as a clinical development partnership with Artiva Biotherapeutics Inc., which will provide it with access to a commercially scalable source of NK cells as the program matures.
Zhuhai Beihai Biotech Co. Ltd. has raised nearly ¥200 million (US$27.5 million) in a series B round slated to support clinical trials for its lead candidates as well as preparations to file an NDA for its core asset, BH-009, an injectable formulation of docetaxel that excludes polysorbate 80 (Tween 80), a surfactant that has been associated with increased risk of adverse events, including hypersensitivity. The company claims that no similar product is currently available worldwide.
CV6 Therapeutics Ltd. raised $9.2 million in grant and equity funding to move a first-in-class inhibitor of deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase) into a phase Ia trial in cancer. The compound, CV6-168, will from the outset be administered in combination with fluorouracil, a mainstay of chemotherapy for the past 60 years.
Alkermes plc’s decision to explore separating its commercial-stage neuroscience business from earlier-stage oncology efforts – forming a distinct, publicly traded company to investigate cancer therapies – drove speculation about the launch of the firm’s Lybalvi (olanzapine and samidorphan), approved by the U.S. FDA in the middle of 2021 for schizophrenia and bipolar I disorder.
Black Friday is still weeks away, but Exelixis Inc. has gone shopping and inked two deals that together are potentially worth more than $1 billion, bolstering its pipeline with cancer drugs from Cybrexa Inc. and Sairopa B.V. Both deals are eye-catching, not just because of their potential value but also because of the technologies involved. Cybrexa’s drug is a peptide-drug conjugate, a class where only one drug is FDA approved and established, and Sairopa is working on an antibody targeting SIRPα, a potential next-generation immunotherapy.
RSS
